Therefore, placing a guarding gene within CSF provides an advantage as long as the cellular checkpoints are not compromised, whereas failure in these checkpoints (i.e. by additional mutations in RB1 and p53) would lead to tumor initiation and/or progression. Here, TP53 is linked to neoplasm.